340B hospitals are marking up discounted drugs by 4.9 times the cost, per a Community Oncology Alliance report; thousands of nurses in Minnesota are striking due to understaffing and overworking; Amgen’s sotorasib performed better than a common chemotherapy for progression-free survival among patients.
A report by the Community Oncology Alliance reveals that hospitals participating in the 340B Drug Discount Program that are located in underserved communities are marking up discounted drugs by up to 11 times the cost. According to self-reported pricing data from these hospitals, top oncology drugs are being priced an average 4.9 times their 340B acquisition costs, after an assumed 34.7% discount. The report also shows that markups vary by drug, with tisagenlecleucel (Kymriah) having the lowest average markup of 3.2 times the cost and fulvestrant (Faslodex) having the highest, at 11.3 times the cost. After excluding 3 chimeric antigen receptor T-cell therapies, the median markup was slightly higher at 5.0 times the 340B hospital acquisition costs.
Around 15,000 nurses in Minnesota began a strike Monday to protest issues surrounding understaffing and overworking at the state’s hospitals. The Washington Post reports this marks the largest private-sector nurses strike in US history. It is expected to last 3 days, with signs pointing to potential strikes in other states. This strike puts the focus on nursing shortages across the United States that have been worsened due to the COVID-19 pandemic, with nurses saying they cannot give their patients adequate care. Minnesota nurses claim some hospital units lack a lead nurse on duty and nurses that just completed their education are being given assignments typically held by more experienced nurses. The nurses on strike are demanding a role in staffing plans, changes to shift scheduling procedures, and higher wages.
Amgen has revealed data highlighting the benefits and limitations of its new lung cancer drug, sotorasib (Lumakras), The Wall Street Journal reports. The pill performed better than the common chemotherapy docetaxel in a late-stage study to help patients survive longer without their tumors worsening. According to the report, 25% of patients who received sotorasib lived for at least 1 year without their cancer worsening vs 10% of patients who received docetaxel. However, the study could not prove the oral medication reduced overall deaths.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
March 28th 2024Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Read More